These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 24174870

  • 1. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA.
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [Abstract] [Full Text] [Related]

  • 2. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study.
    Doesch AO, Mueller S, Konstandin M, Celik S, Erbel C, Kristen A, Frankenstein L, Koch A, Dengler TJ, Ehlermann P, Zugck C, De Geest S, Katus HA.
    Transplant Proc; 2010 Dec; 42(10):4238-42. PubMed ID: 21168673
    [Abstract] [Full Text] [Related]

  • 3. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S, Fujita T, Yoneyama T, Yoneyama T, Koie T, Hashimoto Y, Saitoh H, Funyu T, Narumi S, Ohyama C.
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [Abstract] [Full Text] [Related]

  • 4. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH, Lee SD, Kim YK, Park SJ.
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [Abstract] [Full Text] [Related]

  • 5. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation.
    Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2015 Aug; 9():1217-24. PubMed ID: 25759566
    [Abstract] [Full Text] [Related]

  • 6. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B, Holmdahl J, Sundvall N, Cockburn E, Kilany S, Wennberg L.
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation.
    Beckebaum S, Iacob S, Sweid D, Sotiropoulos GC, Saner F, Kaiser G, Radtke A, Klein CG, Erim Y, de Geest S, Paul A, Gerken G, Cicinnati VR.
    Transpl Int; 2011 Jul; 24(7):666-75. PubMed ID: 21466596
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA, Nagib AM, Donia AF, Denewar AA, Abu-Elmagd MM, Abbas MH, Abdel-Rahman AM, Mashaly ME, Elsaftawy MM, Ghoneim MA.
    Saudi J Kidney Dis Transpl; 2018 Jul; 29(6):1267-1273. PubMed ID: 30588956
    [Abstract] [Full Text] [Related]

  • 12. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
    Agarwal SK, Bhowmik D, Mahajan S, Bagchi S.
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
    [Abstract] [Full Text] [Related]

  • 13. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.
    Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, Dobbels F, Vanrenterghem Y, Kanaan N, ADMIRAD Study Team.
    Transplantation; 2013 Jan 27; 95(2):333-40. PubMed ID: 23263559
    [Abstract] [Full Text] [Related]

  • 14. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A, Tredger JM, Heneghan M, Agarwal K, Samyn M, Heaton ND, O'Grady JG, Aluvihare VR.
    Liver Transpl; 2015 Jan 27; 21(1):29-37. PubMed ID: 25312292
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.
    Lehner LJ, Reinke P, Hörstrup JH, Rath T, Suwelack B, Krämer BK, Budde K, Banas B.
    Clin Transplant; 2018 Jan 27; 32(1):. PubMed ID: 29052906
    [Abstract] [Full Text] [Related]

  • 16. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation.
    Calia R, Lai C, Aceto P, Luciani M, Romagnoli J, Lai S, Gargiulo A, Citterio F.
    Transplant Proc; 2011 May 27; 43(4):1020-3. PubMed ID: 21620041
    [Abstract] [Full Text] [Related]

  • 17. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, Checa MD, Rodríguez A, García JJ, Rufino M, Torres A.
    Transplantation; 2007 Sep 27; 84(6):706-14. PubMed ID: 17893603
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 19. Conversion to generic cyclosporine A in stable chronic patients after heart transplantation.
    Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, Ruhparwar A, Ehlermann P, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2013 May 27; 7():1421-6. PubMed ID: 24348018
    [Abstract] [Full Text] [Related]

  • 20. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul 27; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.